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Over	  the	  last	  ten	  years,	  there	  has	  been	  a	  huge	  shift	  in	  malaria	  diagnosis	  in	  public	  health	  facilities,	  
due	  to	  widespread	  deployment	  of	  rapid	  diagnostic	  tests	  (RDTs),	  which	  are	  accurate,	  quick	  and	  easy	  
to	  use,	  and	  inexpensive.	  There	  are	  calls	  for	  RDTs	  to	  be	  made	  available	  at-­‐scale	  in	  the	  private	  retail	  
sector	  where	  many	  people	  with	  suspected	  malaria	  seek	  care.	  
Retail	  sector	  RDT	  use	  in	  sub-­‐Saharan	  Africa	  (SSA)	  is	  limited	  to	  small-­‐scale	  studies,	  and	  robust	  
evidence	  on	  value	  for	  money	  is	  not	  yet	  available.	  We	  modelled	  the	  cost-­‐effectiveness	  of	  introducing	  
subsidised	  RDTs	  and	  supporting	  interventions	  in	  the	  SSA	  retail	  sector,	  in	  a	  context	  of	  a	  subsidy	  
programme	  for	  first	  line	  antimalarials.	  
Methods	  
We	  developed	  a	  decision	  tree	  that	  follows	  febrile	  patients	  from	  initial	  presentation,	  through	  
diagnosis,	  treatment,	  disease	  progression	  and	  further	  care,	  to	  final	  health	  outcomes.	  We	  modelled	  
results	  for	  three	  ‘treatment	  scenarios’,	  based	  on	  treatment	  parameters	  from	  three	  small-­‐scale	  
studies	  in	  Nigeria	  (TS-­‐N),	  Tanzania	  (TS-­‐T)	  and	  Uganda	  (TS-­‐U),	  under	  low	  and	  medium/high	  
transmission	  (5%	  and	  50%	  Plasmodium	  falciparum	  (parasite)	  positivity	  rates	  (PfPR)	  respectively).	  
Results	  
Cost-­‐effectiveness	  varied	  considerably	  between	  treatment	  scenarios.	  Base	  case	  cost	  per	  disability-­‐
adjusted	  life	  year	  averted	  at	  5%	  PfPR	  was	  $482	  (TS-­‐N)	  and	  $115	  (TS-­‐T),	  and	  at	  50%	  PfPR	  $44	  (TS-­‐N)	  
and	  $45	  (TS-­‐T),	  from	  a	  health	  service	  perspective.	  TS-­‐U	  was	  dominated	  in	  both	  transmission	  settings.	  
Conclusion	  
The	  cost-­‐effectiveness	  of	  subsidised	  RDTs	  is	  strongly	  influenced	  by	  treatment	  practices,	  for	  which	  
further	  evidence	  is	  required	  from	  larger-­‐scale	  operational	  settings.	  However,	  subsidised	  RDT	  
introduction	  could	  promote	  increased	  ACT	  use	  in	  patients	  with	  malaria.	  RDTs	  may	  therefore	  be	  more	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cost-­‐effective	  in	  higher	  transmission	  settings,	  where	  a	  greater	  proportion	  of	  febrile	  patients	  have	  
malaria	  and	  therefore	  benefit	  from	  increased	  antimalarial	  use.	  This	  is	  contrary	  to	  findings	  of	  
previous	  public	  sector	  models,	  where	  RDTs	  were	  most	  cost-­‐effective	  in	  lower	  transmission	  settings	  
as	  they	  reduced	  unnecessary	  antimalarial	  use	  in	  patients	  without	  malaria.	  
SUMMARY  BOX  
What	  is	  already	  known	  about	  this	  subject?	  
• Over	  the	  last	  ten	  years,	  rapid	  diagnostic	  tests	  (RDTs)	  have	  played	  an	  important	  role	  in	  the	  
substantial	  increase	  in	  parasitological	  confirmation	  of	  suspected	  malaria	  cases	  in	  primary	  level	  
public	  health	  facilities.	  
• In	  many	  settings,	  private	  retailers,	  such	  as	  drug	  shops	  and	  small	  pharmacies,	  provide	  the	  
majority	  of	  antimalarials	  but	  rarely	  carry	  out	  parasitological	  diagnosis.	  
• Evidence	  of	  the	  effectiveness	  of	  subsidised	  malaria	  RDTs	  in	  the	  private	  retail	  sector	  in	  sub-­‐
Saharan	  Africa	  (SSA)	  is	  limited	  to	  small-­‐scale	  trials	  and	  pilot	  studies.	  
What	  are	  the	  new	  findings?	  
• RDT	  cost-­‐effectiveness	  in	  the	  SSA	  private	  retail	  sector	  is	  strongly	  influenced	  by	  treatment	  
practices,	  for	  which	  further	  evidence	  is	  required	  from	  larger-­‐scale	  operational	  settings.	  
• Initial	  evidence	  indicates	  that	  subsidised	  RDTs	  may	  promote	  the	  increased	  use	  of	  antimalarials	  in	  
patients	  with	  malaria.	  
What	  are	  the	  recommendations	  for	  policy	  and	  practice?	  
• RDT	  introduction	  may	  be	  more	  cost-­‐effective	  in	  higher	  transmission	  settings,	  where	  a	  greater	  
proportion	  of	  febrile	  patients	  have	  malaria	  and	  therefore	  benefit	  from	  increased	  antimalarial	  
use.	  
• These	  findings	  challenge	  the	  traditional	  view	  of	  RDTs	  as	  primarily	  a	  way	  to	  reduce	  inappropriate	  
antimalarial	  use	  and	  improve	  case	  management	  of	  non-­‐malaria	  cases.	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INTRODUCTION  
It	  is	  now	  over	  a	  decade	  since	  the	  World	  Health	  Organization	  (WHO)	  first	  recommended	  
parasitological	  confirmation	  prior	  to	  treatment	  for	  all	  suspected	  malaria	  cases(1).	  Over	  this	  period	  
there	  has	  been	  a	  major	  increase	  in	  parasitological	  diagnosis	  in	  public	  health	  facilities,	  with	  policy	  
implementation	  accelerated	  by	  two	  key	  developments.	  First,	  inexpensive	  but	  ineffective	  
antimalarials,	  such	  as	  chloroquine,	  were	  replaced	  with	  much	  more	  expensive	  artemisinin	  
combination	  therapies	  (ACTs),	  heightening	  concerns	  about	  the	  waste	  of	  medicines	  arising	  from	  
presumptive	  treatment.	  This	  coincided	  with	  increased	  availability	  of	  malaria	  rapid	  diagnostic	  tests	  
(RDTs),	  which	  are	  quick	  (<20	  minutes),	  accurate,	  simple	  to	  use,	  relatively	  inexpensive,	  and	  avoid	  the	  
need	  for	  functioning	  microscopes	  and	  trained	  microscopists.	  In	  2017,	  82%	  of	  suspected	  public	  sector	  
malaria	  cases	  in	  the	  WHO	  African	  Region	  received	  a	  malaria	  diagnostic	  test,	  compared	  with	  36%	  in	  
2010(2,3)	  and	  it	  is	  estimated	  that	  RDTs	  now	  account	  for	  three-­‐quarters	  of	  all	  such	  tests	  
conducted(3).	  
There	  are	  increasing	  calls	  for	  RDTs	  to	  be	  made	  available	  at-­‐scale	  in	  the	  private	  sector	  as	  well	  –	  in	  
particular	  the	  private	  retail	  sector	  where	  a	  high	  proportion	  of	  people	  with	  suspected	  malaria	  seek	  
care(4-­‐6).	  Private	  retailers,	  primarily	  drug	  shops	  and	  small	  pharmacies,	  provide	  the	  majority	  of	  
antimalarials	  in	  many	  settings	  but	  rarely	  carry	  out	  parasitological	  diagnosis.	  In	  a	  study	  across	  eight	  
countries	  in	  sub-­‐Saharan	  Africa	  (SSA)	  (2014-­‐2015),	  in	  five	  countries	  RDTs	  were	  available	  in	  less	  than	  
10%	  of	  outlets	  that	  stocked	  antimalarials,	  with	  the	  highest	  availability	  in	  Uganda	  being	  only	  
21.5%(7).	  Such	  retailers	  vary	  substantially	  in	  terms	  of	  the	  qualifications	  of	  staff,	  from	  qualified	  
pharmacists	  to	  drug	  sellers	  with	  no	  formal	  health	  training,	  and	  the	  types	  of	  prescription	  drugs	  they	  
are	  permitted	  to	  sell(8,9).	  A	  high	  proportion	  of	  patients	  sold	  antimalarials	  at	  retail	  outlets	  do	  not	  
have	  malaria	  parasitaemia,	  while	  those	  with	  malaria	  often	  receive	  no	  antimalarial	  or	  a	  less	  effective	  
antimalarial	  monotherapy	  instead	  of	  an	  ACT(10).	  It	  has	  been	  argued	  that	  the	  increased	  availability	  of	  
RDTs	  in	  these	  settings	  would	  better	  target	  antimalarial	  treatment	  to	  malaria	  patients	  and	  improve	  
case	  management	  of	  so-­‐called	  ‘non-­‐malarial	  febrile	  illness’	  (NMFI)(11,12).	  However,	  there	  are	  also	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concerns	  of	  misdiagnosis	  due	  to	  a	  lack	  of	  provider	  training	  and	  supervision,	  continued	  over-­‐
treatment	  of	  test-­‐negatives	  with	  ACTs,	  and	  unsafe	  handling	  of	  infectious	  waste(8).	  
Since	  2010,	  there	  have	  been	  moves	  to	  increase	  accessibility	  and	  affordability	  of	  quality-­‐assured	  ACTs	  
in	  the	  private	  sector,	  initially	  through	  the	  Global	  Fund’s	  Affordable	  Medicines	  Facility-­‐malaria	  and	  
subsequently	  the	  Private	  Sector	  Co-­‐Payment	  Mechanism,	  which	  subsidised	  ACT	  prices	  through	  a	  co-­‐
payment	  at	  the	  manufacturer	  level(13,14).	  It	  has	  been	  argued	  that	  a	  similar	  subsidy	  of	  RDTs,	  
together	  with	  a	  continued	  ACT	  subsidy,	  could	  promote	  private	  sector	  RDT	  uptake	  and	  incentivise	  
patients	  to	  purchase	  an	  RDT	  instead	  of	  presumptive	  treatment(15).	  
Robust	  evidence	  on	  the	  impact	  and	  value	  for	  money	  of	  retail	  sector	  RDT	  introduction	  is	  not	  yet	  
available.	  While	  subsidised	  RDTs	  have	  been	  provided	  through	  the	  retail	  sector	  in	  parts	  of	  Asia	  for	  
more	  than	  15	  years(16),	  in	  SSA	  they	  are	  still	  mainly	  limited	  to	  small-­‐scale	  trials	  and	  pilot	  
studies(8,17).	  There	  is	  considerable	  variation	  across	  these	  studies	  in	  the	  impact	  of	  RDT	  introduction	  
on	  the	  likelihood	  of	  receiving	  ‘appropriate’	  treatment	  (e.g.	  an	  ACT	  for	  malaria,	  or	  an	  antibiotic	  for	  a	  
bacterial	  infection)(8).	  There	  is	  only	  one	  published	  empirical	  economic	  evaluation	  of	  RDT	  
introduction	  in	  the	  SSA	  retail	  sector,	  Hansen	  et	  al.	  2017,	  which	  reports	  cost-­‐effectiveness	  in	  terms	  of	  
intermediate	  outcomes	  (cost	  per	  appropriately	  treated	  patient)(18)	  rather	  than	  final	  health	  
outcomes	  (such	  as	  disability-­‐adjusted	  life	  years	  (DALYs)	  averted)(19).	  
To	  our	  knowledge,	  this	  paper	  is	  the	  first	  to	  model	  the	  cost-­‐effectiveness	  of	  subsidised	  malaria	  RDT	  
introduction	  in	  the	  SSA	  private	  sector.	  Unlike	  a	  single	  empirical	  study,	  a	  modelling	  approach	  enables	  
exploration	  of	  cost-­‐effectiveness	  under	  a	  range	  of	  treatment	  practices,	  and	  varying	  levels	  of	  malaria	  
transmission,	  as	  well	  as	  assessing	  sensitivity	  to	  the	  many	  other	  model	  parameters.	  We	  assess	  retail	  
sector	  RDT	  introduction	  in	  the	  context	  of	  an	  existing	  ACT	  subsidy,	  as	  the	  empirical	  evidence	  is	  drawn	  
from	  such	  settings.	  We	  apply	  our	  model	  to	  the	  context	  of	  Plasmodium	  falciparum	  malaria	  in	  SSA,	  
which	  accounts	  for	  over	  90%	  of	  annual	  malaria	  deaths	  globally(3).	  We	  build	  on	  previous	  models	  of	  
RDT	  introduction	  in	  the	  public	  sector(20-­‐22)	  and	  incorporate	  a	  number	  of	  methodological	  
enhancements	  including:	  (i)	  consideration	  of	  patients	  co-­‐infected	  with	  malaria	  and	  bacteria;	  (ii)	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relaxation	  of	  the	  assumption	  that	  all	  patients	  in	  the	  intervention	  arm	  receive	  an	  RDT;	  (iii)	  inclusion	  of	  
treatment	  with	  both	  ACT	  and	  non-­‐ACT	  antimalarials,	  and	  combinations	  of	  different	  treatments;	  and	  
(iv)	  accounting	  for	  the	  impact	  of	  poor	  quality	  drugs	  and	  imperfect	  adherence	  to	  treatment	  by	  
patients	  in	  estimating	  treatment	  effectiveness.	  
METHODS  
Intervention  and  model   structure  
We	  developed	  a	  decision-­‐analytic	  model	  to	  estimate	  the	  incremental	  costs	  and	  outcomes	  of	  large-­‐
scale	  (e.g.	  national)	  introduction	  of	  subsidised	  RDTs	  in	  the	  retail	  sector	  in	  a	  theoretical	  SSA	  setting	  
(‘intervention’),	  against	  a	  comparator	  of	  no	  retail	  sector	  RDT	  introduction	  (‘control’).	  The	  control	  
arm	  includes	  an	  80%	  subsidy	  of	  ACTs	  in	  the	  private	  sector	  but	  no	  availability	  of	  RDTs	  in	  the	  retail	  
sector.	  The	  intervention	  also	  includes	  an	  80%	  ACT	  subsidy	  but	  with	  RDTs	  available	  at	  retail	  outlets,	  
subsidised	  by	  50%	  to	  improve	  affordability,	  and	  supporting	  interventions:	  community	  sensitisation,	  
training	  of	  providers,	  disposal	  of	  waste,	  and	  ongoing	  provider	  monitoring	  (Panel	  1).	  
In	  line	  with	  previous	  public	  sector	  models(20-­‐22),	  we	  use	  a	  decision	  tree	  that	  follows	  febrile	  patients	  
from	  initial	  presentation	  at	  a	  retail	  outlet,	  through	  diagnosis	  and	  initial	  treatment,	  the	  effectiveness	  
of	  any	  treatment,	  possible	  disease	  progression	  and	  further	  care,	  to	  their	  final	  health	  outcomes	  
(Figure	  1	  and	  Supplementary	  File,	  S1).	  Parameter	  values	  for	  RDT	  uptake,	  initial	  treatment	  and	  
supporting	  intervention	  costs	  were	  taken	  from	  selected	  empirical	  studies	  of	  subsidised	  RDT	  
introduction	  in	  the	  retail	  sector.	  All	  other	  parameters	  draw	  on	  a	  wide	  range	  of	  secondary	  sources,	  
including	  previous	  public	  sector	  models.	  Key	  model	  parameters	  are	  shown	  in	  Table	  1,	  and	  all	  other	  
parameters	  in	  the	  Supplementary	  File	  (S2).	  We	  conducted	  the	  analysis	  for	  a	  notional	  cohort	  of	  
100,000	  patients	  with	  uncomplicated	  febrile	  illness	  without	  obvious	  cause,	  presenting	  at	  retail	  
outlets,	  at	  two	  sample	  points	  of	  malaria	  parasitaemia:	  5%	  P.	  falciparum	  positivity	  rate	  (PfPR)	  (a	  ‘low’	  
transmission	  setting)	  and	  50%	  PfPR	  (a	  ‘medium/high’	  transmission	  setting).	  We	  conducted	  sensitivity	  
analysis	  to	  explore	  cost-­‐effectiveness	  across	  the	  full	  range	  of	  PfPR	  (0-­‐90%).	  For	  parameters	  that	  vary	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depending	  on	  the	  intensity	  of	  malaria	  transmission	  (e.g.	  case	  fatality	  rate	  for	  untreated	  malaria)	  we	  
assumed	  different	  values	  for	  the	  ‘low’	  and	  ‘medium/high’	  transmission	  settings(21,23).	  Patients	  
presenting	  with	  fever	  are	  classified	  according	  to	  their	  true	  underlying	  diagnosis	  as	  either:	  malaria,	  
bacterial,	  malaria	  and	  bacterial	  co-­‐infection,	  or	  viral	  only	  (Supplementary	  File,	  S3).	  
Diagnosis  and  initial  treatment  
Estimates	  of	  the	  proportion	  of	  patients	  in	  the	  intervention	  arm	  that	  receive	  an	  RDT	  (‘uptake’)	  were	  
taken	  from	  a	  literature	  review	  by	  Visser	  et	  al.	  of	  empirical	  studies	  of	  RDT	  introduction	  in	  the	  retail	  
sector(8).	  We	  excluded	  one	  study	  conducted	  outside	  of	  SSA(24),	  two	  studies	  where	  RDTs	  were	  
provided	  at	  no	  cost	  to	  patients(25,26),	  and	  one	  study	  where	  information	  on	  uptake	  was	  not	  
available(27).	  We	  also	  excluded	  two	  further	  studies	  where	  data	  on	  RDT	  uptake	  were	  obtained	  from	  
provider	  records	  rather	  than	  mystery	  shoppers	  or	  exit	  interviews(28,29),	  as	  providers	  may	  
exaggerate	  their	  adherence	  to	  study	  protocols	  in	  their	  own	  records.	  RDT	  uptake	  in	  the	  intervention	  
arm	  was	  estimated	  as	  the	  median	  uptake	  (41%)	  of	  the	  nine	  intervention	  arms	  across	  the	  six	  included	  
studies(30-­‐35).	  The	  remaining	  patients	  in	  the	  model’s	  intervention	  arm	  and	  all	  patients	  in	  the	  control	  
arm	  did	  not	  receive	  a	  malaria	  diagnostic	  test	  prior	  to	  treatment.	  We	  also	  tested	  the	  sensitivity	  of	  
results	  to	  changes	  in	  RDT	  uptake,	  based	  on	  the	  lowest	  (8%)	  and	  highest	  (72%)	  uptake	  from	  the	  
included	  studies.	  
To	  obtain	  sources	  for	  initial	  treatment	  parameters	  we	  identified	  published	  studies	  of	  RDT	  
introduction	  in	  the	  SSA	  retail	  sector.	  We	  excluded	  studies	  where	  the	  RDT	  was	  provided	  for	  
free(25,26),	  data	  on	  initial	  treatment	  were	  obtained	  from	  provider	  records(29),	  or	  baseline	  and	  
endline	  data	  were	  obtained	  from	  different	  types	  of	  data	  collection(32).	  This	  led	  to	  the	  inclusion	  of	  
three	  eligible	  studies(28,30,31).	  As	  these	  three	  studies	  reported	  substantially	  different	  impacts	  of	  
RDT	  introduction	  on	  the	  use	  of	  ACTs	  and	  other	  antimalarials,	  we	  modelled	  cost-­‐effectiveness	  
separately	  using	  initial	  treatment	  parameters	  from	  each	  of	  these	  three	  studies	  as	  three	  ‘treatment	  
scenarios’.	  The	  three	  scenarios	  were	  based	  on:	  a	  cluster-­‐randomised	  trial	  at	  private	  retailers	  
(including	  pharmacies	  and	  drug	  shops)	  and	  public	  health	  facilities	  in	  two	  sites	  in	  south-­‐eastern	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Nigeria	  (TS-­‐N)(31);	  a	  non-­‐randomised	  controlled	  trial	  in	  accredited	  drug	  dispensing	  outlets	  in	  two	  
districts	  in	  Tanzania	  (TS-­‐T)(30);	  and	  a	  cluster-­‐randomised	  trial	  of	  drug	  shops	  in	  79	  villages	  in	  eastern	  
Uganda	  (TS-­‐U)(28).	  We	  liaised	  with	  authors	  to	  obtain	  additional	  data	  on	  all	  drugs	  received	  and,	  in	  the	  
case	  of	  TS-­‐N,	  to	  separate	  retail	  sector	  from	  public	  sector	  patients(36-­‐38).	  Data	  were	  categorised	  into	  
seven	  mutually	  exclusive	  treatment	  categories	  (see	  Supplementary	  File,	  S4).	  Figure	  2	  shows	  the	  
treatment	  received	  under	  each	  scenario,	  with	  and	  without	  RDT	  availability.	  The	  treatment	  scenarios	  
differ	  considerably:	  for	  TS-­‐N,	  RDT	  introduction	  increased	  ACT	  use	  (and	  reduced	  other	  antimalarial	  
use)	  even	  for	  those	  not	  tested	  or	  with	  a	  negative	  test,	  whereas	  TS-­‐T	  shows	  an	  increase	  in	  ACT	  use	  for	  
test-­‐positives	  and	  a	  reduction	  for	  test-­‐negatives.	  TS-­‐U	  shows	  a	  similar	  but	  more	  modest	  impact	  on	  
ACT	  use.	  
Treatment  effectiveness  
We	  estimated	  the	  success	  of	  initial	  treatment	  in	  curing	  the	  true	  underlying	  diagnosis	  in	  a	  ‘real	  world’	  
setting	  (‘treatment	  effectiveness’).	  We	  calculated	  the	  probability	  of	  treatment	  effectiveness	  for	  both	  
antimalarials	  and	  antibiotics	  as	  the	  efficacy	  of	  each	  treatment	  less	  a	  percentage	  reduction	  based	  on	  
the	  proportion	  of	  active	  pharmaceutical	  ingredient	  (API)	  consumed	  by	  a	  patient	  (Table	  1).	  
Antimalarial	  efficacy	  estimates	  were	  based	  on	  the	  median	  day	  28	  success	  rate	  in	  SSA	  clinical	  trials	  
reported	  by	  the	  Worldwide	  Antimalarial	  Resistance	  Network(39);	  antibiotic	  efficacy	  was	  based	  on	  
expert	  opinion.	  We	  estimated	  API	  consumed	  as	  the	  product	  of	  the	  average	  percent	  API	  per	  dose	  
(which	  is	  less	  than	  100%	  due	  to	  imperfect	  drug	  quality)	  and	  the	  average	  percent	  of	  a	  dose	  consumed	  
(due	  to	  patient	  adherence	  to	  treatment),	  based	  on	  studies	  of	  antimalarial	  quality(40)	  and	  patient	  
adherence(41).	  
Disease  progression  and  further  care  
We	  assumed	  that	  viral	  infections	  are	  self-­‐resolving.	  For	  infections	  due	  to	  malaria	  and/or	  bacterial	  
infection,	  where	  initial	  treatment	  with	  antimalarials	  or	  antibiotics	  is	  effective	  we	  assumed	  that	  
illness	  resolved	  without	  further	  care.	  Where	  no	  initial	  treatment	  for	  malaria	  or	  bacterial	  infection	  is	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received,	  we	  assumed	  that	  the	  disease	  may	  progress	  from	  an	  uncomplicated	  to	  a	  severe	  state,	  using	  
estimates	  from	  a	  published	  Delphi	  survey	  of	  malaria	  experts(23).	  In	  the	  absence	  of	  data	  on	  
outcomes	  of	  those	  receiving	  ineffective	  treatment,	  we	  assumed	  that	  the	  probability	  of	  progression	  
was	  the	  same	  for	  untreated	  infections.	  We	  explore	  the	  uncertainty	  of	  disease	  progression,	  across	  a	  
wide	  range	  of	  values,	  via	  sensitivity	  analysis.	  
Final  health  outcomes  
Where	  illness	  remains	  uncomplicated,	  full	  recovery	  is	  assumed.	  Where	  illness	  has	  progressed	  to	  
severe,	  different	  case	  fatality	  rates	  are	  assumed	  based	  on	  the	  true	  underlying	  diagnosis	  and	  whether	  
further	  inpatient	  or	  outpatient	  care	  is	  provided(20,23,42,43).	  In	  addition	  to	  death,	  patients	  with	  
severe	  febrile	  illness	  risk	  long-­‐term	  neurological	  sequelae(20,42,43).	  
Costs  
We	  estimated	  incremental	  costs	  as	  the	  difference	  between	  costs	  in	  the	  intervention	  and	  control	  
arms,	  from	  both	  health	  service	  and	  societal	  perspectives,	  in	  2017	  US	  dollars.	  Health	  service	  costs	  
included	  the	  subsidies	  on	  RDTs	  and	  ACTs,	  the	  cost	  of	  further	  outpatient	  or	  inpatient	  care	  at	  public	  
health	  facilities,	  and	  supporting	  intervention	  costs.	  Societal	  costs	  comprised	  health	  service	  costs	  plus	  
direct	  patient	  out-­‐of-­‐pocket	  medical	  costs	  for	  initial	  treatment	  (including	  the	  retail	  price	  of	  RDTs	  and	  
drugs	  received),	  the	  cost	  of	  further	  care	  at	  private	  outpatient	  facilities	  (public	  outpatient	  facilities	  
were	  assumed	  to	  be	  free),	  and	  user	  fees	  associated	  with	  any	  inpatient	  care	  (which	  for	  simplicity	  we	  
assumed	  was	  all	  public	  sector).	  The	  retail	  price	  (i.e.	  cost	  to	  patients)	  of	  an	  RDT	  was	  calculated	  as	  
$0.33,	  and	  the	  retail	  prices	  of	  ACTs	  and	  antibiotics	  per	  course	  of	  treatment	  as	  $1.02	  and	  $0.44,	  
respectively.	  Non-­‐medical	  patient	  costs	  (including	  travel	  costs)	  and	  indirect	  costs	  (including	  lost	  time	  
and	  productivity)	  were	  not	  included	  due	  to	  lack	  of	  available	  data.	  Costs	  to	  retailers	  were	  not	  
included,	  as	  we	  assumed	  that	  retailers	  would	  only	  participate	  if	  they	  could	  cover	  such	  costs	  from	  
RDT	  and	  drug	  sales.	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The	  calculation	  of	  supporting	  intervention	  costs	  is	  described	  in	  the	  Supplementary	  File	  (S5).	  
Community	  sensitisation,	  retailer	  training,	  and	  retailer	  supervision	  costs	  were	  adapted	  from	  a	  similar	  
intervention	  in	  29	  Ugandan	  drug	  shops(18).	  An	  additional	  waste	  collection	  cost	  was	  added,	  equal	  to	  
the	  cost	  of	  supervision.	  The	  Uganda	  study	  reported	  an	  unusually	  low	  number	  of	  febrile	  patients,	  less	  
than	  one	  febrile	  patient	  per	  outlet	  per	  day(29).	  In	  our	  base	  case	  analysis,	  we	  increased	  this	  to	  five	  
febrile	  patients	  per	  outlet	  per	  day	  and	  tested	  the	  impact	  of	  this	  assumption	  via	  sensitivity	  analysis.	  
This	  reduces	  the	  number	  of	  outlets	  required	  to	  be	  trained	  and	  supervised	  for	  the	  modelled	  cohort	  of	  
100,000	  febrile	  patients.	  Including	  an	  assumed	  management	  and	  overhead	  cost,	  supporting	  
intervention	  costs	  are	  estimated	  at	  $0.43	  ($0.21-­‐0.64)	  per	  febrile	  patient	  ($773	  per	  outlet	  per	  year)	  
(Table	  1).	  
Cost-­‐effect iveness  
We	  calculated	  incremental	  cost-­‐effectiveness	  ratios	  (ICERs),	  as	  total	  incremental	  costs	  divided	  by	  
total	  DALYs	  averted,	  for	  the	  intervention	  compared	  with	  the	  control.	  DALYs	  were	  calculated	  as	  the	  
sum	  of	  years	  of	  life	  lost	  and	  years	  of	  life	  with	  disability	  ,	  applying	  a	  discount	  rate	  of	  3%(44),	  African	  
life	  expectancy	  (2006)	  from	  WHO	  life	  tables(45)	  and	  Global	  Burden	  of	  Disease	  disability	  weights(46).	  	  
There	  is	  considerable	  debate	  about	  the	  selection	  of	  appropriate	  cost-­‐effectiveness	  
thresholds(47,48).	  We	  compared	  ICERs	  for	  each	  of	  our	  treatment	  scenarios	  against	  six	  country-­‐
specific	  thresholds	  calculated	  by	  Ochalek	  et	  al.	  2018,	  which	  incorporate	  individual	  country	  estimates	  
of	  health	  opportunity	  costs(49).	  The	  six	  countries	  all	  received	  private	  sector	  ACT	  subsidies	  as	  part	  of	  
the	  Private	  Sector	  Co-­‐payment	  Mechanism(13).	  Ochalek	  et	  al.	  employ	  four	  different	  approaches	  for	  
estimating	  the	  impact	  of	  changes	  in	  health	  expenditure	  on	  morbidity	  and	  mortality;	  we	  use	  the	  
mean	  of	  the	  country-­‐specific	  thresholds	  calculated	  from	  these	  four	  approaches,	  for	  each	  country.	  All	  
thresholds	  were	  converted	  to	  2017	  US	  dollars(50),	  giving	  thresholds	  (per	  DALY	  averted)	  of:	  
Madagascar	  $84,	  Uganda	  $115,	  Nigeria	  $182,	  Tanzania	  $283,	  Ghana	  $521,	  and	  Kenya	  $630.	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Sensit iv ity   analys is   
We	  explored	  the	  impact	  of	  individual	  parameter	  uncertainty	  on	  cost-­‐effectiveness,	  in	  terms	  of	  both	  
ICERs	  and	  net	  monetary	  benefit	  (NMB),	  using	  deterministic	  sensitivity	  analysis.	  NMB	  is	  expressed	  as	  
the	  incremental	  value	  of	  health	  benefits	  in	  monetary	  terms	  (calculated	  by	  multiplying	  DALYs	  averted	  
by	  the	  value	  of	  such	  benefits	  at	  the	  appropriate	  cost-­‐effectiveness	  threshold),	  minus	  the	  incremental	  
costs	  of	  the	  intervention(51).	  
We	  also	  conducted	  probabilistic	  sensitivity	  analysis	  (PSA)	  to	  ascertain	  the	  combined	  impact	  of	  
parameter	  uncertainty	  on	  incremental	  cost-­‐effectiveness.	  Probability	  distributions	  were	  assigned	  to	  
relevant	  parameters,	  including	  beta	  distributions	  for	  binomial	  probabilities,	  Dirichlet	  distributions	  for	  
multinomial	  probabilities,	  and	  gamma	  distributions	  for	  costs(51).	  Using	  Monte	  Carlo	  simulation,	  
10,000	  samples	  were	  drawn	  from	  the	  parameter	  distributions	  to	  generate	  incremental	  cost	  and	  
incremental	  DALYs	  averted	  at	  both	  5%	  and	  50%	  PfPR.	  
Patient  and  publ ic    involvement  
Neither	  patients	  nor	  the	  public	  were	  involved	  in	  the	  study.	  
RESULTS  
At	  5%	  PfPR,	  the	  majority	  (85.8%)	  of	  the	  cohort	  of	  100,000	  febrile	  patients	  had	  a	  viral	  infection,	  which	  
is	  unaffected	  by	  antimalarial	  or	  antibiotic	  drugs;	  9.2%	  had	  a	  bacterial	  infection	  only,	  4.7%	  had	  
malaria	  only,	  and	  0.3%	  had	  malaria	  and	  bacterial	  co-­‐infection.	  At	  50%	  PfPR,	  48%	  of	  patients	  had	  a	  
viral	  infection,	  2%	  bacterial	  infection	  only,	  47%	  malaria	  only,	  and	  3%	  co-­‐infection	  (Supplementary	  
File,	  S2).	  
Table	  2	  shows	  the	  incremental	  costs,	  health	  outcomes,	  and	  cost-­‐effectiveness	  of	  subsidised	  RDT	  
introduction	  for	  each	  of	  the	  treatment	  scenarios	  at	  5%	  and	  50%	  PfPR.	  
13	  
Intermediate  outcomes  
The	  different	  parameters	  used	  for	  initial	  treatment,	  based	  on	  the	  three	  treatment	  scenarios,	  led	  to	  
different	  intermediate	  outcomes	  in	  terms	  of	  the	  use	  of	  ACTs,	  other	  antimalarials,	  all	  antimalarials,	  
and	  antibiotics.	  The	  introduction	  of	  RDTs	  increased	  ACT	  use	  for	  patients	  with	  malaria	  in	  all	  three	  
treatment	  scenarios.	  TS-­‐T	  and	  TS-­‐U	  also	  resulted	  in	  better	  targeting	  of	  ACTs,	  with	  reductions	  in	  the	  
proportion	  of	  people	  without	  parasitaemia	  that	  received	  an	  ACT.	  This	  was	  due	  to	  a	  reduction	  in	  the	  
likelihood	  of	  receiving	  an	  ACT	  with	  a	  negative	  test	  compared	  to	  the	  control	  arm.	  In	  TS-­‐N,	  the	  
intervention	  more	  than	  doubled	  the	  number	  of	  people	  without	  malaria	  that	  received	  an	  ACT	  –	  
largely	  due	  to	  the	  much	  higher	  likelihood	  that	  an	  untested	  patient	  would	  receive	  an	  ACT	  in	  the	  
intervention	  arm	  (49%)	  compared	  to	  patients	  in	  the	  control	  arm	  (18%).	  
In	  all	  three	  treatment	  scenarios,	  RDT	  introduction	  led	  to	  modest	  reductions	  in	  antibiotic	  use	  in	  test-­‐
negative	  patients,	  including	  those	  with	  assumed	  bacterial	  infection.	  This	  is	  contrary	  to	  evidence	  from	  
other	  public	  and	  private	  sector	  studies	  indicating	  that	  RDTs	  may	  lead	  to	  overall	  increases	  in	  
antibiotic	  use	  by	  as	  much	  as	  25	  percentage	  points(29,52,53).	  We	  therefore	  conducted	  sensitivity	  
analysis	  on	  the	  cost-­‐effectiveness	  impact	  of	  substantially	  higher	  antibiotic	  use	  for	  test-­‐negative	  
patients	  (see	  below).	  
Final   health  outcomes  
In	  two	  treatment	  scenarios	  (TS-­‐N	  and	  TS-­‐T),	  the	  intervention	  led	  to	  a	  net	  reduction	  in	  deaths	  
(Supplementary	  File,	  S6).	  This	  was	  due	  to	  a	  reduction	  in	  	  deaths	  as	  a	  result	  of	  increased	  ACT	  or	  other	  
antimalarial	  use	  in	  patients	  infected	  with	  malaria,	  and	  was	  more	  pronounced	  in	  the	  50%	  PfPR	  
setting.	  There	  was	  a	  comparatively	  modest	  increase	  in	  deaths	  relating	  to	  bacterial	  infection,	  
primarily	  due	  to	  reduced	  antibiotic	  use.	  In	  TS-­‐U,	  the	  intervention	  led	  to	  an	  increase	  in	  deaths	  from	  
both	  malaria	  and	  bacterial	  infection.	  This	  was	  largely	  due	  to	  the	  reduction	  in	  the	  likelihood	  of	  
receiving	  either	  an	  antimalarial	  or	  an	  antibiotic	  for	  the	  majority	  (59%)	  of	  patients	  in	  the	  intervention	  
arm	  who	  were	  not	  tested.	  Consequently,	  the	  model	  predicted	  a	  wide	  range	  of	  estimates	  of	  DALYs	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averted	  across	  the	  treatment	  scenarios;	  at	  50%	  PfPR,	  from	  1,217	  DALYs	  averted	  for	  TS-­‐N	  to	  942	  
DALYs	  incurred	  for	  TS-­‐U.	  
Costs  
Incremental	  health	  service	  costs	  were	  positive	  for	  all	  three	  treatment	  scenarios	  in	  both	  transmission	  
settings	  (5%	  and	  50%	  PfPR),	  largely	  as	  a	  result	  of	  supporting	  intervention	  and	  RDT	  subsidy	  costs	  in	  
the	  intervention	  arm.	  Supporting	  intervention	  costs	  were	  by	  far	  the	  largest	  component,	  comprising	  
78-­‐92%	  of	  total	  health	  service	  costs.	  TS-­‐N	  had	  the	  highest	  incremental	  health	  service	  cost	  in	  both	  the	  
transmission	  settings	  shown	  (e.g.	  $55,022	  at	  5%	  PfPR)	  due	  to	  the	  cost	  of	  the	  ACT	  subsidy	  for	  the	  
large	  increase	  in	  ACT	  use	  in	  the	  intervention	  arm.	  
Unlike	  the	  other	  treatment	  scenarios,	  TS-­‐U	  had	  a	  positive	  incremental	  health	  service	  cost	  for	  further	  
care	  (e.g.	  $1,537	  at	  5%	  PfPR).	  This	  is	  due	  to	  fewer	  patients	  in	  the	  intervention	  arm	  receiving	  
appropriate	  treatment	  and	  therefore	  progressing	  to	  severe	  disease,	  compared	  with	  the	  control	  arm.	  
Incremental	  patient	  out-­‐of-­‐pocket	  costs	  were	  driven	  primarily	  by	  RDT	  costs,	  based	  on	  a	  retail	  price	  
of	  $0.33	  per	  test.	  Incremental	  patient	  out-­‐of-­‐pocket	  costs	  comprised	  11-­‐24%	  of	  total	  incremental	  
societal	  costs	  (combined	  health	  service	  costs	  and	  patient	  out-­‐of-­‐pocket	  costs).	  
Cost-­‐effect iveness  
The	  base	  case	  ICER	  (health	  service	  perspective)	  at	  5%	  PfPR	  was	  $482	  and	  $115	  per	  DALY	  averted	  for	  
TS-­‐N	  and	  TS-­‐T,	  respectively.	  At	  50%	  PfPR,	  the	  base	  case	  ICER	  was	  $44	  (TS-­‐N)	  and	  $45	  (TS-­‐T)	  per	  DALY	  
averted.	  For	  TS-­‐U,	  the	  intervention	  was	  dominated	  (i.e.	  less	  effective	  and	  more	  expensive	  than	  the	  
control)	  at	  both	  5%	  and	  50%	  PfPR	  (Table	  2).	  Comparing	  the	  ICERs	  against	  the	  six	  country-­‐specific	  
thresholds,	  both	  TS-­‐N	  and	  TS-­‐T	  would	  be	  considered	  cost-­‐effective	  for	  all	  six	  countries	  at	  50%	  PfPR.	  
At	  5%	  PfPR,	  TS-­‐T	  would	  be	  considered	  cost-­‐effective	  for	  all	  six	  countries	  except	  Madagascar,	  but	  TS-­‐
N	  would	  only	  be	  considered	  cost-­‐effective	  for	  two	  countries	  (Kenya	  and	  Ghana).	  Results	  from	  a	  
societal	  perspective	  follow	  a	  similar	  pattern	  but	  as	  one	  would	  expect	  are	  somewhat	  less	  cost-­‐
effective,	  reflecting	  the	  additional	  patient	  out-­‐of-­‐pocket	  medical	  costs	  included	  (Table	  2).	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Sensit iv ity   analys is   
Deterministic  sensitivity  analysis  
NMB	  (from	  a	  health	  service	  perspective)	  of	  the	  three	  treatment	  scenarios	  across	  the	  range	  of	  PfPR	  
(0-­‐90%)	  is	  shown	  in	  the	  Supplementary	  File	  (S7).	  NMB	  has	  been	  calculated	  using	  a	  value	  of	  health	  
benefit	  equal	  to	  the	  lowest	  and	  highest	  of	  the	  six	  country-­‐specific	  cost-­‐effectiveness	  thresholds	  –	  
Madagascar	  ($84)	  and	  Kenya	  ($630),	  respectively.	  In	  the	  two	  non-­‐dominated	  treatment	  scenarios,	  
TS-­‐N	  and	  TS-­‐T,	  the	  intervention	  is	  more	  cost-­‐effective	  (i.e.	  NMB	  increases)	  at	  higher	  levels	  of	  PfPR.	  
This	  is	  primarily	  due	  to	  increased	  ACT	  use	  in	  malaria	  patients	  in	  the	  intervention	  arm	  compared	  with	  
the	  control,	  the	  impact	  of	  which	  is	  more	  pronounced	  as	  PfPR	  (and	  therefore	  the	  proportion	  of	  
patients	  with	  malaria)	  increases.	  NMB	  becomes	  positive	  (and	  the	  intervention	  cost-­‐effective)	  at	  the	  
point	  where	  the	  value	  of	  incremental	  health	  benefit	  generated	  exceeds	  incremental	  cost.	  In	  the	  
medium/high	  transmission	  setting,	  NMB	  is	  positive	  for	  TS-­‐T	  across	  the	  full	  range	  of	  PfPR	  at	  the	  Kenya	  
threshold,	  and	  above	  30%	  PfPR	  at	  the	  Madagascar	  threshold;	  NMB	  is	  positive	  for	  TS-­‐N	  above	  20%	  
PfPR	  at	  the	  Kenya	  threshold	  and	  35%	  PfPR	  at	  the	  Madagascar	  threshold.	  
Table	  3	  illustrates	  the	  sensitivity	  of	  the	  ICER	  (from	  a	  health	  service	  perspective)	  to	  changes	  in	  
individual	  parameters,	  for	  each	  treatment	  scenario	  at	  5%	  and	  50%	  PfPR.	  Results	  are	  relatively	  robust	  
to	  changes	  in	  individual	  parameter	  values	  at	  50%	  PfPR,	  but	  much	  less	  so	  in	  the	  lower	  transmission	  
setting.	  At	  5%	  PfPR,	  the	  intervention	  for	  TS-­‐N	  is	  dominated	  at	  either	  the	  low	  or	  high	  bound	  of	  the	  
plausible	  range	  of	  uncertainty	  for	  7	  of	  16	  the	  parameters	  shown;	  TS-­‐T	  remains	  cost-­‐effective	  for	  the	  
majority	  of	  the	  country	  thresholds	  across	  most	  of	  the	  16	  parameters	  tested.	  TS-­‐N	  and	  TS-­‐T	  are	  
particularly	  sensitive	  at	  5%	  PfPR	  to	  uncertainty	  in	  the	  impact	  of	  RDTs	  on	  treatment	  received	  
(antimalarial	  with	  positive	  RDT	  result,	  antibiotic	  with	  negative	  RDT	  result),	  as	  well	  as	  the	  probability	  
that	  malaria	  becomes	  severe	  without	  (effective)	  treatment,	  the	  probability	  that	  a	  severe	  patient	  
receives	  inpatient	  care,	  and	  the	  case	  fatality	  rate	  of	  untreated	  (and,	  to	  a	  lesser	  extent,	  treated)	  
malaria.	  Both	  TS-­‐N	  and	  TS-­‐T	  are	  also	  sensitive	  to	  changes	  in	  the	  discount	  rate	  and	  in	  the	  supporting	  
intervention	  cost	  per	  febrile	  patient.	  TS-­‐U	  remains	  dominated	  across	  the	  range	  of	  all	  parameters	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tested,	  except	  where	  we	  assumed	  that	  the	  initial	  treatment	  parameters	  for	  patients	  not	  receiving	  a	  
test	  would	  be	  unchanged	  between	  the	  control	  and	  intervention	  arms	  (i.e.	  RDT	  introduction	  would	  
not	  influence	  the	  initial	  treatment	  received	  by	  untested	  patients	  in	  the	  intervention	  arm),	  and	  at	  5%	  
PfPR	  where	  the	  probability	  that	  a	  patient	  with	  a	  negative	  test	  result	  receives	  an	  antibiotic	  increases	  
by	  25	  percentage	  points.	  
Probabilistic  sensitivity  analysis  
Individual	  results	  of	  the	  10,000	  simulations	  generated	  by	  the	  PSA	  are	  provided	  in	  the	  Supplementary	  
File	  (S8).	  Cost-­‐effectiveness	  acceptability	  curves	  were	  calculated	  from	  10,000	  simulations	  generated	  
by	  the	  PSA	  (Figure	  3).	  At	  5%	  PfPR,	  the	  probability	  of	  cost-­‐effectiveness	  at	  the	  highest	  threshold,	  
Kenya	  ($630),	  is	  47%	  for	  TS-­‐N	  and	  72%	  for	  TS-­‐T,	  from	  a	  health	  service	  perspective.	  The	  probability	  of	  
cost-­‐effectiveness	  is	  higher	  at	  50%	  PfPR:	  64%	  for	  TS-­‐N	  and	  80%	  for	  TS-­‐T.	  TS-­‐U	  never	  approaches	  a	  
material	  probability	  of	  cost-­‐effectiveness	  even	  at	  the	  highest	  of	  the	  six	  country	  thresholds.	  The	  
probability	  of	  cost-­‐effectiveness	  is	  reduced	  for	  all	  treatment	  scenarios	  when	  patient	  out-­‐of-­‐pocket	  
costs	  are	  included.	  
DISCUSSION  
In	  this	  paper	  we	  have	  proposed	  a	  number	  of	  methodological	  developments	  in	  modelling	  malaria	  RDT	  
introduction,	  and	  presented	  novel	  results	  on	  the	  cost-­‐effectiveness	  of	  subsidised	  RDT	  introduction	  in	  
the	  context	  of	  an	  existing	  ACT	  subsidy	  in	  the	  SSA	  private	  sector.	  The	  results	  of	  our	  modelling	  were	  
not	  conclusive	  on	  whether	  subsidised	  RDT	  introduction	  is	  cost-­‐effective	  in	  such	  circumstances.	  The	  
three	  small-­‐scale	  studies	  we	  drew	  on	  for	  initial	  treatment	  parameters	  varied	  considerably	  in	  terms	  of	  
how	  patients	  were	  treated	  in	  relation	  to	  whether	  or	  not	  they	  had	  a	  test	  and	  the	  test	  result,	  and	  this	  
resulted	  in	  very	  different	  cost-­‐effectiveness	  results	  for	  the	  three	  treatment	  scenarios.	  This	  is	  
explored	  in	  more	  detail	  below.	  Moreover,	  implementation	  has	  yet	  to	  be	  conducted	  at	  a	  national	  
scale,	  meaning	  that	  there	  is	  limited	  evidence	  on	  the	  feasibility,	  effectiveness	  and	  cost	  in	  operational	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settings(8),	  and	  it	  is	  possible	  that	  the	  growth	  in	  awareness	  and	  acceptance	  of	  RDTs	  over	  time	  may	  
also	  influence	  these	  outcomes.	  	  
The	  studies	  used	  for	  the	  three	  treatment	  scenarios	  were	  all	  conducted	  in	  the	  context	  of	  substantial	  
subsidisation	  of	  RDTs	  and	  ACTs,	  and	  with	  supporting	  intervention	  costs	  borne	  by	  the	  health	  service.	  
Since	  these	  studies	  were	  conducted,	  ACT	  subsidies	  have	  been	  reduced	  in	  many	  countries(13).	  This	  
may	  limit	  the	  generalisability	  of	  results,	  particularly	  in	  settings	  with	  a	  lower	  level	  of	  ACT	  
subsidisation	  or	  none	  at	  all.	  Without	  an	  ACT	  subsidy,	  overall	  antimalarial	  use	  and	  the	  proportion	  of	  
antimalarials	  that	  are	  ACTs	  may	  be	  lower,	  which	  may	  reduce	  the	  impact	  of	  RDT	  introduction	  on	  
increased	  antimalarial	  (and	  particularly	  ACT)	  use.	  Without	  subsidisation	  of	  RDTs	  and	  supporting	  
interventions,	  RDT	  uptake	  would	  likely	  be	  lower,	  reducing	  the	  impact	  of	  RDT	  introduction	  on	  initial	  
treatment	  received	  by	  patients	  in	  the	  intervention	  arm.	  This	  underscores	  the	  need	  for	  further	  
studies	  at	  scale	  of	  RDT	  use	  in	  the	  retail	  sector,	  and	  particularly	  in	  settings	  where	  private	  sector	  ACT	  
subsidies	  are	  low	  or	  non-­‐existent.	  
The	  differences	  in	  cost-­‐effectiveness	  between	  treatment	  scenarios	  and	  transmission	  settings	  are	  
underpinned	  by	  the	  substantial	  differences	  in	  the	  impact	  of	  RDTs	  on	  the	  treatment	  received	  in	  each	  
scenario.	  In	  both	  TS-­‐N	  and	  TS-­‐T,	  RDT	  introduction	  leads	  to	  an	  overall	  increase	  in	  antimalarial	  use	  for	  
malaria	  cases	  (+5%	  and	  +10%	  respectively),	  but	  the	  increase	  in	  ACT	  use	  for	  malaria	  cases	  is	  much	  
higher	  for	  TS-­‐N	  (+211%)	  than	  TS-­‐T	  (+25%).	  For	  bacterial	  cases,	  antibiotic	  use	  is	  reduced	  by	  up	  to	  30%	  
in	  TS-­‐N	  but	  as	  little	  as	  4%	  in	  TS-­‐T.	  As	  a	  result,	  improved	  health	  outcomes	  of	  malaria	  cases	  due	  to	  
increased	  antimalarial	  use	  are	  higher	  for	  TS-­‐N,	  and	  diminished	  health	  outcomes	  of	  bacterial	  cases	  
due	  to	  reduced	  antibiotic	  use	  are	  less	  pronounced	  for	  TS-­‐T	  than	  for	  TS-­‐N.	  These	  differences	  help	  
explain	  why	  both	  scenarios	  are	  more	  cost-­‐effective	  in	  higher	  transmission	  settings,	  where	  the	  
proportion	  of	  malaria	  cases	  is	  higher	  (and	  the	  proportion	  of	  bacterial	  cases	  is	  lower),	  and	  also	  why	  
TS-­‐N	  is	  more	  cost-­‐effective	  than	  TS-­‐T	  at	  5%	  PfPR	  and	  vice	  versa	  at	  50%	  PfPR.	  
Our	  analysis	  has	  a	  number	  of	  other	  limitations.	  As	  with	  all	  models	  of	  this	  kind,	  parameters	  are	  
subject	  to	  a	  high	  amount	  of	  uncertainty.	  Whilst	  the	  range	  of	  possible	  values	  for	  each	  parameter	  was	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assessed	  and	  incorporated	  into	  the	  PSA,	  the	  true	  confidence	  levels	  of	  many	  of	  these	  values	  are	  not	  
known	  precisely.	  The	  probabilities	  of	  progression	  to	  severe	  illness	  and	  case	  fatality	  rates	  for	  
untreated	  severe	  illness	  were	  taken	  from	  a	  Delphi	  study	  that	  reported	  substantial	  variation	  in	  
estimates	  between	  experts(23).	  Disease	  progression	  for	  patients	  receiving	  ineffective	  treatment	  was	  
assumed	  to	  be	  the	  same	  as	  for	  those	  where	  no	  treatment	  was	  received.	  Supporting	  intervention	  
costs	  were	  adapted	  and	  scaled	  up	  from	  a	  single	  drug	  shop	  study	  in	  Uganda(6),	  adjusted	  based	  on	  an	  
assumed	  number	  of	  febrile	  patients	  per	  outlet	  per	  day.	  
The	  model	  assumes	  that	  the	  symptoms	  of	  all	  parasitaemic	  patients	  are	  causally	  attributable	  to	  either	  
malaria	  alone	  or	  a	  malaria	  and	  bacterial	  co-­‐infection.	  However,	  malaria	  infections	  are	  frequently	  
asymptomatic,	  particularly	  in	  high	  transmission	  settings(54).	  In	  such	  cases,	  symptoms	  may	  be	  due	  to	  
a	  self-­‐resolving	  viral	  infection.	  Such	  patients	  would	  not	  benefit	  from	  the	  increased	  likelihood	  of	  
antimalarial	  treatment	  due	  to	  a	  positive	  RDT	  result,	  nor	  would	  they	  be	  likely	  to	  progress	  to	  severe	  
disease	  where	  the	  treatment	  received	  was	  ineffective.	  The	  model	  may	  therefore	  overstate	  the	  
incremental	  effectiveness	  of	  the	  intervention	  in	  resolving	  symptoms	  of	  parasitaemic	  patients.	  
Uncertainty	  relating	  to	  aetiology	  of	  fever	  is	  partly	  incorporated	  in	  the	  wide	  range	  of	  uncertainty	  
modelled	  for	  antimalarial	  effectiveness	  and	  disease	  progression	  parameters,	  including	  a	  lower	  
probability	  of	  disease	  progression	  in	  medium/high	  transmission	  than	  low	  transmission	  settings.	  
However,	  the	  cost-­‐effectiveness	  of	  RDT	  introduction	  may	  nevertheless	  be	  overstated	  for	  patients	  
with	  asymptomatic	  malaria,	  and	  in	  settings	  where	  the	  proportion	  of	  such	  patients	  is	  high.	  
We	  assumed	  no	  change	  in	  initial	  treatment-­‐seeking	  behaviour	  as	  a	  result	  of	  the	  intervention.	  It	  is	  
possible	  that	  RDT	  introduction	  would	  encourage	  a	  greater	  proportion	  of	  febrile	  patients	  to	  seek	  
treatment	  in	  the	  retail	  sector,	  with	  implications	  for	  further	  care-­‐seeking	  and	  health	  outcomes(55).	  
We	  also	  assumed	  that	  the	  true	  underlying	  diagnosis	  profile	  of	  untested	  patients	  in	  the	  intervention	  
arm	  was	  the	  same	  as	  that	  for	  the	  population	  in	  the	  control	  arm.	  In	  practice,	  untested	  patients	  in	  the	  
intervention	  arm	  may	  have	  less	  serious	  illnesses	  than	  the	  control	  arm,	  as	  they	  were	  not	  tested	  
despite	  the	  availability	  of	  RDTs.	  The	  model	  also	  does	  not	  incorporate	  the	  potential	  impact	  of	  RDT	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introduction	  on	  antimalarial	  and	  antibiotic	  resistance,	  or	  any	  possible	  side-­‐effects	  of	  treatment.	  We	  
also	  do	  not	  include	  the	  potential	  benefits	  of	  retail	  sector	  RDT	  introduction	  for	  enhancing	  sector-­‐wide	  
malaria	  surveillance,	  were	  such	  data	  to	  be	  integrated	  into	  existing	  systems.	  
Our	  findings	  challenge	  the	  traditional	  rationale	  of	  RDTs	  as	  primarily	  to	  reduce	  inappropriate	  
antimalarial	  use	  and	  improve	  case	  management	  of	  NMFIs(29,56-­‐58).	  This	  view	  was	  informed	  by	  
public	  sector	  models	  indicating	  that	  RDTs	  are	  more	  cost-­‐effective	  in	  lower	  transmission	  settings	  
where	  there	  are	  relatively	  few	  malaria	  cases	  and	  antimalarials	  are	  overused	  and	  untargeted(20).	  
However,	  our	  analysis	  shows	  that	  where	  RDTs	  lead	  to	  an	  increase	  in	  ACT	  (or	  other	  antimalarial)	  use,	  
particularly	  for	  patients	  with	  a	  positive	  RDT	  result,	  improved	  health	  outcomes	  for	  malaria	  cases	  can	  
be	  a	  strong	  driver	  of	  cost-­‐effectiveness.	  This	  is	  perhaps	  more	  likely	  in	  the	  retail	  sector,	  where	  pre-­‐
RDT	  antimalarial	  use	  is	  relatively	  low	  compared	  with	  the	  public	  health	  sector(59).	  
TS-­‐U	  is	  dominated	  across	  the	  range	  of	  PfPR,	  as	  the	  intervention	  results	  in	  an	  11%	  reduction	  in	  
antimalarials	  for	  malaria	  cases	  (despite	  an	  8%	  increase	  in	  ACTs	  for	  this	  group)	  and	  a	  10%	  reduction	  in	  
antibiotics	  for	  bacterial	  cases.	  This	  largely	  relates	  to	  initial	  treatment	  received	  by	  the	  untested	  group	  
in	  the	  intervention	  arm,	  where	  the	  use	  of	  other	  (non-­‐ACT)	  antimalarials	  is	  a	  third	  lower,	  and	  
antibiotic	  use	  16%	  lower,	  than	  the	  control	  arm;	  TS-­‐U	  was	  reasonably	  cost-­‐effective	  at	  50%	  PfPR	  
when	  we	  assumed	  in	  the	  sensitivity	  analysis	  that	  the	  untested	  group	  in	  the	  intervention	  received	  the	  
same	  treatment	  as	  the	  control.	  Based	  on	  our	  assumed	  uptake,	  almost	  three-­‐fifths	  (59%)	  of	  patients	  
in	  the	  intervention	  arm	  did	  not	  receive	  a	  test.	  TS-­‐U	  shows	  the	  importance	  of	  this	  untested	  group	  in	  
determining	  cost-­‐effectiveness,	  and	  in	  strategies	  to	  promote	  RDT	  uptake.	  It	  also	  highlights	  the	  need	  
to	  better	  understand	  what	  illnesses	  untested	  patients	  are	  likely	  to	  have,	  what	  treatment	  they	  
receive,	  and	  their	  health	  outcomes.	  
This	  analysis	  also	  provides	  an	  insight	  on	  the	  importance	  of	  monitoring	  other	  (non-­‐ACT)	  antimalarial	  
use.	  Even	  though	  the	  efficacy	  of	  ACTs	  is	  considerably	  higher	  than	  for	  other	  antimalarials,	  non-­‐ACT	  
antimalarials	  are	  still	  commonly	  used	  in	  the	  retail	  sector	  in	  many	  settings.	  For	  a	  patient	  with	  malaria,	  
receiving	  a	  non-­‐ACT	  antimalarial	  may	  be	  more	  effective	  than	  not	  receiving	  any	  antimalarial	  at	  all.	  All	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treatment	  scenarios	  reported	  relatively	  high	  levels	  of	  other	  antimalarial	  use;	  in	  TS-­‐U	  in	  particular,	  
the	  reduction	  in	  non-­‐ACT	  antimalarial	  use	  for	  untested	  patients	  in	  the	  intervention	  arm	  was	  a	  
contributor	  to	  the	  intervention	  being	  dominated.	  Changes	  in	  other	  antimalarial	  use	  can	  have	  a	  
material	  impact	  on	  cost-­‐effectiveness,	  particularly	  in	  the	  retail	  sector	  where	  other	  antimalarials	  may	  
comprise	  a	  larger	  proportion	  of	  total	  antimalarial	  use	  than	  in	  other	  settings.	  Therefore	  it	  is	  important	  
that	  other,	  non-­‐ACT	  antimalarials	  continue	  to	  be	  monitored	  in	  future	  studies,	  particularly	  for	  large-­‐
scale	  implementations.	  
In	  the	  three	  treatment	  scenarios	  modelled,	  RDT	  introduction	  did	  not	  appear	  to	  have	  a	  strong	  impact	  
on	  antibiotic	  use	  for	  RDT-­‐negative	  patients.	  In	  all	  treatment	  scenarios	  and	  both	  transmission	  settings	  
there	  was	  a	  modest	  reduction	  in	  antibiotic	  use	  in	  patients	  with	  a	  bacterial	  illness,	  compared	  with	  the	  
control;	  this	  contributed	  to	  poorer	  health	  outcomes	  for	  bacterial	  cases	  and	  had	  a	  negative	  impact	  on	  
cost-­‐effectiveness.	  This	  reduced	  antibiotic	  use	  is	  in	  contrast	  to	  previous	  research	  showing	  a	  general	  
increase	  in	  antibiotic	  prescribing	  in	  public	  and	  private	  intervention	  settings,	  particularly	  amongst	  
patients	  with	  negative	  malaria	  tests(52)	  and	  counter	  to	  expectations	  that	  RDTs	  would	  lead	  to	  
improved	  management	  of	  NMFI	  cases.	  The	  absence	  of	  increased	  antibiotic	  use	  could	  be	  related	  to	  
possible	  restrictions	  on	  antibiotic	  prescribing	  in	  the	  retail	  sector	  and	  the	  referral	  to	  other	  settings	  of	  
patients	  testing	  negative.	  The	  reduction	  could	  also	  result	  from	  increased	  monitoring,	  and	  hence	  
improved	  compliance,	  by	  retail	  outlets	  in	  the	  intervention	  arms.	  Given	  these	  results,	  we	  examined	  
the	  impact	  of	  an	  increase	  of	  25	  percentage	  points	  in	  antibiotics	  received	  by	  patients	  with	  a	  negative	  
test	  result	  –	  similar	  to	  the	  increase	  seen	  for	  test-­‐negative	  patients	  in	  another	  retail	  sector	  study(29).	  
Such	  an	  increase	  would	  improve	  the	  health	  outcomes	  of	  bacterial	  cases	  and	  substantially	  enhance	  
the	  cost-­‐effectiveness	  of	  RDT	  introduction	  in	  lower	  transmission	  settings.	  Nevertheless,	  it	  highlights	  
the	  need	  for	  improved	  diagnosis	  of	  patients	  with	  bacterial	  infection	  in	  order	  to	  better	  target	  
antibiotics	  to	  patients	  who	  need	  them.	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CONCLUSION  
The	  cost-­‐effectiveness	  of	  subsidised	  RDTs	  in	  the	  SSA	  retail	  sector	  is	  strongly	  influenced	  by	  treatment	  
practices	  and	  how	  these	  are	  affected	  by	  RDT	  introduction,	  for	  which	  further	  evidence	  is	  required	  
from	  larger-­‐scale	  operational	  settings.	  Notwithstanding	  this,	  initial	  evidence	  suggests	  that	  the	  
introduction	  of	  subsidised	  RDTs	  could	  promote	  the	  increased	  use	  of	  ACTs	  and	  other	  antimalarials	  in	  
patients	  with	  malaria.	  As	  a	  result,	  RDTs	  may	  be	  cost-­‐effective	  particularly	  in	  higher	  transmission	  
settings,	  where	  a	  greater	  proportion	  of	  febrile	  patients	  have	  malaria	  and	  therefore	  benefit	  from	  
increased	  antimalarial	  use.	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TABLES  
Panel	  1.	  Description	  of	  intervention	  and	  control	  arms	  
Control	  (no	  RDTs)	  
• No	  RDTs	  available	  in	  private	  retail	  outlets.	  
• ACTs	  subsidised	  in	  the	  private	  sector.	  
Intervention	  (RDTs	  available)	  
• Introduction	  of	  RDTs,	  with	  50%	  subsidy,	  in	  private	  retail	  
outlets	  (uptake	  41%).	  
• Supporting	  interventions:	  community	  sensitisation	  on	  the	  
benefits	  and	  availability	  of	  RDTs,	  training	  of	  providers	  in	  safe	  
and	  effective	  RDT	  use	  and	  case	  management	  protocols	  (3-­‐4	  
day	  workshop),	  monitoring	  and	  supervision	  of	  outlets,	  waste	  
disposal.	  
• ACTs	  subsidised	  in	  the	  private	  sector.	  
	  
Table	  1.	  Key	  cost-­‐effectiveness	  model	  parameters	  
Parameter	   Best	  estimate	  (Range	  for	  PSA)	   Distribution	  for	  PSA	   Source(s)	  
Proportion	  of	  patients	  under	  5	  
years	  
0.40	  (0.30-­‐0.50)	   Beta	   (20)	  
True	  underlying	  diagnosis	  
Malaria	  cases	  with	  bacterial	  co-­‐
infection	  
0.06	  (0.03-­‐0.174)	   Beta	   (60,61)	  
NMFI	  cases	  that	  are	  bacterial	  
infection	  
0.10	  (0.013-­‐0.15)	   Beta	   (20,62)	  
Diagnosis	  (intervention	  arm	  only)	  
Patients	  receiving	  RDT	  
(‘uptake’)	  
0.41	  (0.08-­‐0.72)	   Beta	   (8)	  
RDT	  sensitivity	   0.948	  (0.931-­‐0.961)	   Beta	   (63)	  
RDT	  specificity	   0.952	  (0.631-­‐0.967)	   Beta	   (29,63)	  
Initial	  treatment	  
Proportion	  of	  patients	  receiving	  
an	  ACT,	  non-­‐ACT	  antimalarial,	  
antibiotic,	  other	  drug,	  or	  no	  
drug	  
See	  Figure	  2	  and	  Supplementary	  File	  
(S4)	  
Dirichlet	   (28,30,31,36-­‐38)	  
Treatment	  effectiveness	  
ACT	  efficacy	  (for	  malaria)	   0.955	  (0.82-­‐1.00)	   Beta	   (39)	  
Other	  antimalarial	  efficacy	  (for	  
malaria)	  
0.78	  (0.183-­‐0.97)	   Beta	   (39)	  
Antibiotic	  efficacy	  (for	  bacterial	  
infection)	  
0.80	  (0.72-­‐0.88)	   Beta	   Assumption	  (range:	  
+/-­‐	  10%)	  
Proportion	  of	  stated	  API	  in	  drug	  
(drug	  quality)	  
0.92	  (0.828-­‐1.011)	   Gamma	   (40)	  (range:	  +/-­‐	  10%)	  
Proportion	  of	  required	  dose	  
consumed	  (adherence	  to	  
treatment)	  
0.892	  (0.5-­‐1.0)	   Beta	   (41)	  (range:	  
assumption)	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Parameter	   Best	  estimate	  (Range	  for	  PSA)	   Distribution	  for	  PSA	   Source(s)	  
Reduction	  in	  treatment	  efficacy	  


























Disease	  progression	  and	  further	  care	  
Malaria	  case	  progresses	  to	  

























Bacterial	  case	  progresses	  to	  






















Severe	  case	  receives	  further	  
(inpatient)	  care	  
0.75	  (0.19-­‐0.88)	   Beta	   Assumption	  (range:	  
(20))	  
Final	  health	  outcomes	  
CFR	  of	  severe	  malaria	  receiving	  
inpatient	  care	  
0.10	  (0.05-­‐0.15)	   Beta	   (20,42)	  


















CFR	  of	  severe	  bacterial	  infection	  
receiving	  inpatient	  care	  
0.15	  (0.10-­‐0.20)	   Beta	   (20)	  
CFR	  of	  severe	  bacterial	  infection	  

















Implementation	  costs	  (2017	  USD)	  *	  
RDT	  ex-­‐manufacturer	  price	   0.22	  (0.17-­‐0.28)	   Gamma	   (65)	  (range:	  +/-­‐	  25%)	  
RDT	  subsidy	  (%	  ex-­‐manufacturer	  
price)	  
0.50	  (0.40-­‐0.60)	   Beta	   Assumption	  
ACT	  ex-­‐manufacturer	  price	   0.68	  (0.51-­‐1.56)	   Gamma	   (66)	  
ACT	  subsidy	  (%	  ex-­‐manufacturer	  
price)	  
0.80	  (0.70-­‐0.90)	   Beta	   Assumption	  
Inpatient	  cost	  per	  day	  †	   4.33	  (3.25-­‐17.72)	   Gamma	   (67)	  
Supporting	  intervention	  cost	  
per	  febrile	  patient	  
0.43	  (0.21-­‐0.64)	   Gamma	   See	  Supplementary	  
File	  (S5)	  
NMFI:	  non-­‐malarial	  febrile	  illness.	  API:	  active	  pharmaceutical	  ingredient.	  CFR:	  case	  fatality	  rate.	  *	  All	  costs	  were	  adjusted	  to	  
2017	  US	  dollars	  using	  the	  median	  of	  the	  five	  year	  annual	  average	  GDP	  deflator	  in	  the	  six	  countries	  participating	  in	  the	  
Private	  Sector	  Co-­‐payment	  Mechanism(68).	  †	  Inpatient	  cost	  is	  bed-­‐day	  cost	  only;	  excludes	  cost	  of	  treatment.	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Table	  2.	  Incremental	  costs,	  outcomes,	  and	  cost-­‐effectiveness	  of	  introducing	  subsidized	  malaria	  
RDTs	  for	  100,000	  febrile	  patients	  in	  three	  private	  retail	  sector	  treatment	  scenarios	  (TS-­‐N,	  TS-­‐T,	  TS-­‐
U),	  at	  5%	  and	  50%	  PfPR	  (2017	  USD)	  
	   5%	  PfPR	   50%	  PfPR	  
TS-­‐N	   TS-­‐T	   TS-­‐U	   TS-­‐N	   TS-­‐T	   TS-­‐U	  
Incremental	  health	  service	  costs	  (USD)	  
RDT	   7,462	   7,462	   7,462	   7,462	   7,462	   7,462	  
Initial	  treatment	   4,700	   -­‐3,058	   -­‐1,186	   6,070	   -­‐649	   -­‐375	  
Further	  care	   -­‐71	   -­‐733	   1,537	   -­‐3,338	   -­‐2,813	   2,464	  
Supporting	  intervention	   42,931	   42,931	   42,931	   42,931	   42,931	   42,931	  
Total	  incremental	  health	  
service	  costs	  
55,022	   46,602	   50,743	   53,125	   46,931	   52,481	  
Incremental	  health	  service	  
costs	  per	  febrile	  patient	  
0.55	   0.47	   0.51	   0.53	   0.47	   0.52	  
Incremental	  patient	  OOP	  costs	  (USD)	  
RDT	   13,530	   13,530	   13,530	   13,530	   13,530	   13,530	  
Initial	  treatment	   2,740	   -­‐7,282	   -­‐5,773	   4,648	   -­‐2,377	   -­‐3,837	  
Further	  care	   -­‐31	   -­‐228	   467	   -­‐1,770	   -­‐1,438	   1,193	  
Total	  incremental	  patient	  OOP	  
costs	  
16,239	   6,020	   8,224	   16,409	   9,714	   10,886	  
Incremental	  patient	  OOP	  costs	  
per	  febrile	  patient	  
0.16	   0.06	   0.08	   0.16	   0.10	   0.11	  
Total	  incremental	  societal	  costs	  
(USD)	  
71,261	   52,622	   58,967	   69,534	   56,646	   63,368	  
Incremental	  societal	  costs	  per	  
febrile	  patient	  
0.71	   0.53	   0.59	   0.70	   0.57	   0.63	  
Incremental	  intermediate	  outcomes	  
Of	  patients	  with	  malaria*,	  no.	  (%	  













Of	  patients	  without	  malaria†,	  













Of	  patients	  with	  malaria*,	  no.	  (%	  
change)	  that	  get	  other	  













Of	  patients	  without	  malaria†,	  
no.	  (%	  change)	  that	  get	  other	  













Of	  patients	  with	  malaria*,	  no.	  (%	  














Of	  patients	  without	  malaria†,	  














Of	  patients	  with	  bacterial	  















	   5%	  PfPR	   50%	  PfPR	  
TS-­‐N	   TS-­‐T	   TS-­‐U	   TS-­‐N	   TS-­‐T	   TS-­‐U	  
Of	  patients	  without	  bacterial	  














Incremental	  final	  health	  outcomes	  –	  DALYS	  averted	  
P.	  falciparum	  malaria	   631	   488	   -­‐373	   1,276	   988	   -­‐754	  
Bacterial	   -­‐523	   -­‐93	   -­‐378	   -­‐115	   -­‐19	   -­‐81	  
Viral	   0	   0	   0	   0	   0	   0	  
Co-­‐infection	   6	   9	   -­‐12	   56	   79	   -­‐107	  
All	  febrile	  illness	   114	   404	   -­‐763	   1,217	   1,047	   -­‐942	  
Cost-­‐effectiveness	  (USD)	  	  
Health	  service	  costs	  per	  DALY	  
averted	  
482	   115	   Dominated	   44	   45	   Dominated	  
Societal	  cost	  per	  DALY	  averted	   624	   130	   Dominated	   57	   54	   Dominated	  
OOP:	  out-­‐of-­‐pocket.*	  Patients	  with	  malaria:	  patients	  with	  malaria	  only	  plus	  patients	  with	  co-­‐infection.	  †	  Patients	  without	  
malaria:	  patients	  with	  a	  non-­‐malarial	  febrile	  illness	  (NMFI)	  (bacterial	  or	  viral).	  ‡	  Patients	  without	  bacterial	  infection:	  
patients	  with	  viral	  NMFI	  plus	  patients	  with	  malaria	  only.	  
	  
	  
